Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 102Breast Neoplasms 81Neoplasms 72Neoplasm Metastasis 63Melanoma 63Leukemia, Myeloid, Acute 58Ovarian Neoplasms 54Lymphoma, Non-Hodgkin 52Prostatic Neoplasms 50Colorectal Neoplasms 50Multiple Myeloma 49Glioblastoma 48Pancreatic Neoplasms 47Lung Neoplasms 45Recurrence 41Carcinoma, Renal Cell 40Squamous Cell Carcinoma of Head and Neck 37Leukemia, Lymphocytic, Chronic, B-Cell 37Triple Negative Breast Neoplasms 35Myelodysplastic Syndromes 30Lymphoma, Large B-Cell, Diffuse 28Glioma 28Stomach Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell 27Brain Neoplasms 27Lymphoma, Follicular 26Endometrial Neoplasms 26Lymphoma 25Carcinoma, Hepatocellular 24

Interventions

Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Pancreatic cancer, adult × Clear all
NCT03854110 2025-09-11

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Geistlich Pharma AG

Phase 1 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic cancer, adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡